PTPN1 and obesity due to melanocortin 4 receptor deficiency: The observed increased activity of 2h against PTP1B would make it possible for this potential allosteric site inhibitor) to enhance insulin sensitivity and thus act as an effective therapeutic for the treatment of T2D and obesity.